title: Pulmonary resection for invasive Aspergillus infections in immunocompromised patients.
abstract: Standard antifungal medical therapy of invasive pulmonary aspergillosis that occurs in immunocompromised patients with hematologic diseases with neutropenia or in liver transplant recipients results in less than a 5% survival. In view of these dismal mortality rates, we adopted an aggressive approach with resection of the involved area of lung along with systemic antifungal therapy when localized invasive pulmonary aspergillosis developed in these patients. Between January 1987 and December 1993, 14 patients with hematologic diseases and 2 liver transplant recipients underwent resection of acute localized pulmonary masses suggestive of invasive pulmonary aspergillosis a median of 7.5 days (range 1 to 45 days) after the diagnosis was clinically suggested and confirmed by chest computed tomographic scans. Operative procedures done included two pneumonectomies, one bilobectomy with limited thoracoplasty, nine lobectomies, and five wedge resections (one patient with hematologic disease had two procedures). All patients were treated before and after the operation with antifungal agents. Nine (64%) of 14 patients with hematologic disease and 2 (100%) of 2 liver transplant recipients survived the hospitalization with no evidence of recurrent Aspergillus infection after a median 8 months of follow-up (range 3 to 82 months). The five hospital deaths (all patients with hematologic diseases) occurred a median of 20 days after operation from diffuse alveolar hemorrhage in three, graft-versus-host disease in one, and multiple organ system failure with presumed disseminated Aspergillus infection in one. Four of the five deaths were in patients with allogeneic bone marrow transplants. Two of the three patients requiring resection of multiple foci of infection died, as did the only patient who was preoperatively ventilator dependent. In immunocompromised patients with hematologic diseases or liver transplantation with invasive pulmonary aspergillosis, early pulmonary resection should be strongly considered when the characteristic clinical and radiographic pictures appear.
authors.affiliation: Section of Cardiothoracic Surgery, University of Nebraska Medical Center, Omaha, USA.
authors.forename: L A
authors.initials: LA
authors.lastname: Robinson
authors.forename: E C
authors.initials: EC
authors.lastname: Reed
authors.forename: T A
authors.initials: TA
authors.lastname: Galbraith
authors.forename: A
authors.initials: A
authors.lastname: Alonso
authors.forename: A L
authors.initials: AL
authors.lastname: Moulton
authors.forename: W H
authors.initials: WH
authors.lastname: Fleming
mesh_terms: D000328:Adult; D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use; D001228:Aspergillosis / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006402:Hematologic Diseases / Q000276:immunology*; D017052:Hospital Mortality; D006801:Humans; D016867:Immunocompromised Host; D016031:Liver Transplantation / Q000276:immunology*; D008168:Lung / Q000000981:diagnostic imaging; D008172:Lung Diseases, Fungal / Q000188:drug therapy / Q000276:immunology / Q000401:mortality / Q000601:surgery*; D008297:Male; D011013:Pneumonectomy; D012189:Retrospective Studies; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B